HC Wainwright Estimates Alpha Cognition Q2 Earnings

Alpha Cognition Inc. (NASDAQ:ACOG) – Investment analysts at HC Wainwright issued their Q2 2027 earnings per share estimates for shares of Alpha Cognition in a research note issued to investors on Wednesday, April 8th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0.10) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock.

Alpha Cognition (NASDAQ:ACOG) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). The company had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $4.41 million. Alpha Cognition had a negative return on equity of 68.21% and a negative net margin of 202.23%.

Separately, Wall Street Zen cut Alpha Cognition from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $18.00.

Alpha Cognition Trading Down 4.6%

Alpha Cognition stock opened at $6.64 on Thursday. The stock has a market cap of $144.55 million, a PE ratio of -5.72 and a beta of 2.51. The stock has a 50-day moving average price of $5.62 and a 200 day moving average price of $6.08. Alpha Cognition has a 52 week low of $3.75 and a 52 week high of $11.54.

Institutional Trading of Alpha Cognition

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Berkshire Asset Management LLC PA grew its holdings in Alpha Cognition by 50.7% in the 3rd quarter. Berkshire Asset Management LLC PA now owns 17,824 shares of the company’s stock valued at $116,000 after buying an additional 6,000 shares during the period. Villere ST Denis J & Co. LLC grew its holdings in Alpha Cognition by 13.2% in the 4th quarter. Villere ST Denis J & Co. LLC now owns 73,875 shares of the company’s stock valued at $480,000 after buying an additional 8,617 shares during the period. Green Alpha Advisors LLC purchased a new stake in Alpha Cognition in the 4th quarter valued at about $72,000. Geode Capital Management LLC purchased a new stake in Alpha Cognition in the 2nd quarter valued at about $112,000. Finally, Massar Capital Management LP purchased a new stake in Alpha Cognition in the 2nd quarter valued at about $116,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.